Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn by Dan Ollendorf, Chief Scientific Officer and Director of HTA Methods and Engagement at the Institute for Clinical and Economic Review, adding:
“New initiative by ICER NICE and Canada’s HTA on evaluation of the pharmacoeconomic impact of new therapies highlighted by Dan Ollendorf. Another step in the global move toward value-based therapeutic options.”
Quoting Dan Ollendorf’s post:
“It’s critical not to underestimate the importance of this initiative – allowing independent and scientific conversation when such conversations are currently under attack.”
More posts featuring Tanja Obradovic.